AAPL325.69+0.56 (+0.17%) ▲|ABBV260.34+0.35 (+0.13%) ▲|ABT110.89+1.96 (+1.80%) ▲|ACN187.69-0.40 (-0.21%) ▼|ADBE280.82-5.27 (-1.84%) ▼|AMAT438.52-3.33 (-0.75%) ▼|AMD456.62-2.99 (-0.65%) ▼|AMGN441.36+3.24 (+0.74%) ▲|AMT172.50-3.53 (-2.00%) ▼|AMZN255.12+0.20 (+0.08%) ▲|AVGO368.94-0.75 (-0.20%) ▼|AXP329.70+5.51 (+1.70%) ▲|BA208.84+3.18 (+1.55%) ▲|BAC62.64+0.65 (+1.05%) ▲|BKNG199.42+3.73 (+1.91%) ▲|BLK1,111.54-16.56 (-1.47%) ▼|BMY67.71+0.79 (+1.18%) ▲|BNY162.20+1.69 (+1.05%) ▲|BRK-B505.20+2.87 (+0.57%) ▲|C134.30+1.76 (+1.33%) ▲|CAT790.36+11.20 (+1.44%) ▲|CL90.23+0.60 (+0.67%) ▲|CMCSA26.88+0.58 (+2.19%) ▲|COF216.92+5.58 (+2.64%) ▲|COP137.24+1.05 (+0.77%) ▲|COST921.73-18.23 (-1.94%) ▼|CRM258.33+0.22 (+0.09%) ▲|CSCO109.47-0.27 (-0.25%) ▼|CVS97.19-0.41 (-0.42%) ▼|CVX212.49+1.44 (+0.68%) ▲|DE691.98+15.90 (+2.35%) ▲|DHR209.65+2.72 (+1.31%) ▲|DIS108.46+2.24 (+2.11%) ▲|DUK120.57+0.18 (+0.15%) ▲|EMR149.10+1.47 (+1.00%) ▲|FDX317.89-6.99 (-2.15%) ▼|GD365.98-3.43 (-0.93%) ▼|GE330.31-0.78 (-0.24%) ▼|GEV921.89+23.36 (+2.60%) ▲|GILD149.58-0.35 (-0.23%) ▼|GM84.80-0.84 (-0.98%) ▼|GOOG334.31+2.28 (+0.69%) ▲|GOOGL337.76+2.74 (+0.82%) ▲|GS1,005.10+2.54 (+0.25%) ▲|HD317.95-1.82 (-0.57%) ▼|HON205.35-4.63 (-2.21%) ▼|IBM231.78+0.38 (+0.16%) ▲|INTC89.77+0.80 (+0.90%) ▲|INTU343.00-1.94 (-0.56%) ▼|ISRG370.69+1.44 (+0.39%) ▲|JNJ275.44+4.25 (+1.57%) ▲|JPM355.86+0.91 (+0.26%) ▲|KO88.57+0.57 (+0.64%) ▲|LIN488.47+1.71 (+0.35%) ▲|LLY1,164.70+4.70 (+0.41%) ▲|LMT533.83-10.68 (-1.96%) ▼|LOW199.95-0.10 (-0.05%) ▼|LRCX287.31-2.90 (-1.00%) ▼|MA588.70+7.60 (+1.31%) ▲|MCD260.27-0.85 (-0.32%) ▼|MDLZ62.53+0.92 (+1.49%) ▲|MDT92.84+0.80 (+0.87%) ▲|META595.21+16.67 (+2.88%) ▲|MMM168.31-1.93 (-1.13%) ▼|MO69.67+0.10 (+0.14%) ▲|MRK151.69+1.83 (+1.22%) ▲|MS212.29+1.25 (+0.59%) ▲|MSFT496.75-4.27 (-0.85%) ▼|MU952.16+18.72 (+2.00%) ▲|NEE82.93-0.01 (-0.01%) ▼|NFLX82.39+1.58 (+1.95%) ▲|NKE38.25+0.13 (+0.33%) ▲|NOW137.17-5.73 (-4.01%) ▼|NVDA224.69+7.25 (+3.33%) ▲|ORCL146.16+4.84 (+3.42%) ▲|PEP140.42+0.63 (+0.45%) ▲|PFE29.04+0.49 (+1.72%) ▲|PG147.61+1.40 (+0.96%) ▲|PLTR169.24-10.68 (-5.94%) ▼|PM187.20+0.05 (+0.02%) ▲|QCOM169.75+3.14 (+1.88%) ▲|RTX201.54-3.63 (-1.77%) ▼|SBUX107.13+0.98 (+0.92%) ▲|SCHW109.00+0.72 (+0.66%) ▲|SO88.25+0.16 (+0.18%) ▲|SPG209.49-2.38 (-1.12%) ▼|T26.04+0.04 (+0.14%) ▲|TMO608.84+8.34 (+1.39%) ▲|TMUS186.77+4.61 (+2.53%) ▲|TSLA352.94-3.15 (-0.88%) ▼|TXN254.76+1.42 (+0.56%) ▲|UBER76.64+1.40 (+1.86%) ▲|UNH399.82+3.52 (+0.89%) ▲|UNP290.59-0.03 (-0.01%) ▼|UPS103.15+0.49 (+0.48%) ▲|USB62.83+1.62 (+2.65%) ▲|V379.85+7.18 (+1.93%) ▲|VZ50.35+0.05 (+0.11%) ▲|WFC89.66+2.62 (+3.01%) ▲|WMT105.92-0.01 (0.00%) ▼|XOM164.92+0.37 (+0.22%) ▲|AAPL325.69+0.56 (+0.17%) ▲|ABBV260.34+0.35 (+0.13%) ▲|ABT110.89+1.96 (+1.80%) ▲|ACN187.69-0.40 (-0.21%) ▼|ADBE280.82-5.27 (-1.84%) ▼|AMAT438.52-3.33 (-0.75%) ▼|AMD456.62-2.99 (-0.65%) ▼|AMGN441.36+3.24 (+0.74%) ▲|AMT172.50-3.53 (-2.00%) ▼|AMZN255.12+0.20 (+0.08%) ▲|AVGO368.94-0.75 (-0.20%) ▼|AXP329.70+5.51 (+1.70%) ▲|BA208.84+3.18 (+1.55%) ▲|BAC62.64+0.65 (+1.05%) ▲|BKNG199.42+3.73 (+1.91%) ▲|BLK1,111.54-16.56 (-1.47%) ▼|BMY67.71+0.79 (+1.18%) ▲|BNY162.20+1.69 (+1.05%) ▲|BRK-B505.20+2.87 (+0.57%) ▲|C134.30+1.76 (+1.33%) ▲|CAT790.36+11.20 (+1.44%) ▲|CL90.23+0.60 (+0.67%) ▲|CMCSA26.88+0.58 (+2.19%) ▲|COF216.92+5.58 (+2.64%) ▲|COP137.24+1.05 (+0.77%) ▲|COST921.73-18.23 (-1.94%) ▼|CRM258.33+0.22 (+0.09%) ▲|CSCO109.47-0.27 (-0.25%) ▼|CVS97.19-0.41 (-0.42%) ▼|CVX212.49+1.44 (+0.68%) ▲|DE691.98+15.90 (+2.35%) ▲|DHR209.65+2.72 (+1.31%) ▲|DIS108.46+2.24 (+2.11%) ▲|DUK120.57+0.18 (+0.15%) ▲|EMR149.10+1.47 (+1.00%) ▲|FDX317.89-6.99 (-2.15%) ▼|GD365.98-3.43 (-0.93%) ▼|GE330.31-0.78 (-0.24%) ▼|GEV921.89+23.36 (+2.60%) ▲|GILD149.58-0.35 (-0.23%) ▼|GM84.80-0.84 (-0.98%) ▼|GOOG334.31+2.28 (+0.69%) ▲|GOOGL337.76+2.74 (+0.82%) ▲|GS1,005.10+2.54 (+0.25%) ▲|HD317.95-1.82 (-0.57%) ▼|HON205.35-4.63 (-2.21%) ▼|IBM231.78+0.38 (+0.16%) ▲|INTC89.77+0.80 (+0.90%) ▲|INTU343.00-1.94 (-0.56%) ▼|ISRG370.69+1.44 (+0.39%) ▲|JNJ275.44+4.25 (+1.57%) ▲|JPM355.86+0.91 (+0.26%) ▲|KO88.57+0.57 (+0.64%) ▲|LIN488.47+1.71 (+0.35%) ▲|LLY1,164.70+4.70 (+0.41%) ▲|LMT533.83-10.68 (-1.96%) ▼|LOW199.95-0.10 (-0.05%) ▼|LRCX287.31-2.90 (-1.00%) ▼|MA588.70+7.60 (+1.31%) ▲|MCD260.27-0.85 (-0.32%) ▼|MDLZ62.53+0.92 (+1.49%) ▲|MDT92.84+0.80 (+0.87%) ▲|META595.21+16.67 (+2.88%) ▲|MMM168.31-1.93 (-1.13%) ▼|MO69.67+0.10 (+0.14%) ▲|MRK151.69+1.83 (+1.22%) ▲|MS212.29+1.25 (+0.59%) ▲|MSFT496.75-4.27 (-0.85%) ▼|MU952.16+18.72 (+2.00%) ▲|NEE82.93-0.01 (-0.01%) ▼|NFLX82.39+1.58 (+1.95%) ▲|NKE38.25+0.13 (+0.33%) ▲|NOW137.17-5.73 (-4.01%) ▼|NVDA224.69+7.25 (+3.33%) ▲|ORCL146.16+4.84 (+3.42%) ▲|PEP140.42+0.63 (+0.45%) ▲|PFE29.04+0.49 (+1.72%) ▲|PG147.61+1.40 (+0.96%) ▲|PLTR169.24-10.68 (-5.94%) ▼|PM187.20+0.05 (+0.02%) ▲|QCOM169.75+3.14 (+1.88%) ▲|RTX201.54-3.63 (-1.77%) ▼|SBUX107.13+0.98 (+0.92%) ▲|SCHW109.00+0.72 (+0.66%) ▲|SO88.25+0.16 (+0.18%) ▲|SPG209.49-2.38 (-1.12%) ▼|T26.04+0.04 (+0.14%) ▲|TMO608.84+8.34 (+1.39%) ▲|TMUS186.77+4.61 (+2.53%) ▲|TSLA352.94-3.15 (-0.88%) ▼|TXN254.76+1.42 (+0.56%) ▲|UBER76.64+1.40 (+1.86%) ▲|UNH399.82+3.52 (+0.89%) ▲|UNP290.59-0.03 (-0.01%) ▼|UPS103.15+0.49 (+0.48%) ▲|USB62.83+1.62 (+2.65%) ▲|V379.85+7.18 (+1.93%) ▲|VZ50.35+0.05 (+0.11%) ▲|WFC89.66+2.62 (+3.01%) ▲|WMT105.92-0.01 (0.00%) ▼|XOM164.92+0.37 (+0.22%) ▲|
22.6 C
New York
Wednesday, September 2, 2026

Tag: products

New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma

TALVEY® plus DARZALEX FASPRO® with or without pomalidomide showed progression-free survival of up to 81% and overall survival of up to 89% at 24 monthsMonumenTAL-3 is the...

Innoscience Secures Final Victory in Patent Lawsuit as China’s Supreme Court Upholds Injunction Against Infineon GaN Products

SUZHOU, China, June 13, 2026 /PRNewswire/ -- In a landmark decision for the global semiconductor industry, the Supreme People's Court of China has officially...

Innoscience Secures Final Victory in Patent Lawsuit as China’s Supreme Court Upholds Injunction Against Infineon GaN Products

SUZHOU, China, June 13, 2026 /PRNewswire/ -- In a landmark decision for the global semiconductor industry, the Supreme People's Court of China has officially...

To Go Fast and Far: Why Africa’s Businesses Are Rebuilding Technology in 2026

CAPE TOWN, South Africa, June 13, 2026 /PRNewswire/ -- This is exactly why Junkies Coder an Africa-based software engineering company has launched its Agentic AI...

EpiCooler Product Information Updated As Consumer Interest In Portable AC Grows In 2026

Kaunas, Lithuania, June 13, 2026 (GLOBE NEWSWIRE) --

An informational overview examining EpiCooler Portable AC Product Details, Publicly available product disclosures and what consumers often consider when researching portable cooling devices in 2026

Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

DALLAS, June 12, 2026 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative wellness products, announced today the closing of its previously announced private placement priced at-the-market under Nasdaq rules for the purchase and sale of 3,883,496 shares of its common stock (or pre-funded warrants in lieu thereof), Series A-1 preferred investment options to purchase up to an aggregate of 3,883,496 shares of common stock and Series A-2 preferred investment options to purchase up to an aggregate of 3,883,496 shares of common stock at a purchase price of $1.03 per share of common stock (or pre-funded warrant in lieu thereof) and associated preferred investment options.

Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type...

SAN DIEGO, June 12, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced the completion of its rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tinlarebant. Tinlarebant is an investigational, once-daily oral therapy for the treatment of Stargardt disease type 1 (STGD1), a rare, inherited retinal disease caused by mutations in the ABCA4 gene that leads to progressive and irreversible vision loss. STGD1 affects an estimated 53,000 people in the U.S. alone, and there are currently no approved treatment options for the disease.

Angel Yeast Releases 2025 Sustainability Report as Company Marks 40th Anniversary

SHANGHAI, June 12, 2026 /PRNewswire/ -- Angel Yeast (SSE: 600298), one of the world's leading yeast manufacturers, recently marked its 40th anniversary with the release...

Angel Yeast Releases 2025 Sustainability Report as Company Marks 40th Anniversary

SHANGHAI, June 13, 2026 /PRNewswire/ -- Angel Yeast (SSE: 600298), one of the world's leading yeast manufacturers, recently marked its 40th anniversary with the release...

Angel Yeast Releases 2025 Sustainability Report as Company Marks 40th Anniversary

SHANGHAI, June 13, 2026 /PRNewswire/ -- Angel Yeast (SSE: 600298), one of the world's leading yeast manufacturers, recently marked its 40th anniversary with the release...

Angel Yeast Releases 2025 Sustainability Report as Company Marks 40th Anniversary

SHANGHAI, June 12, 2026 /CNW/ -- Angel Yeast (SSE: 600298), one of the world's leading yeast manufacturers, recently marked its 40th anniversary with the release...

Angel Yeast Releases 2025 Sustainability Report as Company Marks 40th Anniversary

SHANGHAI, June 12, 2026 /PRNewswire/ -- Angel Yeast (SSE: 600298), one of the world's leading yeast manufacturers, recently marked its 40th anniversary with the release...

HASA Inc. Acquires Swimming Pool Chemicals Manufacturer Bio-Dex Laboratories, Inc.

VALENCIA, Calif., June 12, 2026 /PRNewswire/ -- HASA Inc. (www.hasa.com), a leading producer and distributor of high-quality water treatment solutions, today announced the acquisition of Bio–Dex Laboratories,...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsProducts